Manufacturing Process Innovation in the Pharmaceutical Industry

Abstract

Problem definition: Process innovation is commonly claimed to be a major source of competitive advantage for firms. Despite this perceived influence, it has received substantially less attention than product innovation, and much uncertainty remains about its true association with firm performance. We investigate the relationship between a pharmaceutical firm’s portfolio of manufacturing process innovations and its economic performance. Academic/practical relevance: We uniquely conduct a multidimensional evaluation of a firm’s portfolio of manufacturing process innovations at the product level. This allows a quantitative evaluation of both the relative benefit of the different dimensions of a portfolio as well as the potential complementarities between these in different technological landscapes. Methodology: Through a collaboration with expert patent attorneys, we develop a unique longitudinal data set that combines secondary data and evaluations of a firm’s portfolio of process patents along two key dimensions: novelty and scope. We conduct econometric analyses for a large-scale sample of active pharmaceutical ingredients (APIs) whose product patents have expired and for which process innovation is thus the main source of competitive advantage. Results: We find a positive association between the presence of manufacturing process innovation and firm performance. However, although portfolio’s scope appears to always be beneficial to performance, the effect of novelty alone depends on the ruggedness of the technological landscape: negative in smoother landscapes and positive in more rugged landscapes. Results further suggest that novelty and scope of a portfolio of process innovations are complementary across technological landscapes. Managerial implications: Our results provide important practical insights that can inform the organization and execution of the research and development process across high-technology industries. In particular, although process innovations can be economically beneficial, investing in high-novelty process innovations without a corresponding high scope could jeopardize payoffs, especially in technological landscapes that are relatively smooth.